Back to List View Graph View

Myc

Myc refers to a gene encoding the MYC family of transcription factors, which are central regulators of cell growth, metabolism, proliferation, differentiation, and apoptosis.

Where the papers sit

14 papers from the last 6 months study myc directly · updated from PubMed 7 Nov 2026

Study type 0 clinical trials · 1 observational · 5 human data · 4 preclinical · 4 unclassified

Themes 3 themes · 1 paradigm shift

  • Oncogene Alterations in Aggressive Tumors

    Genomic rearrangement and amplification are central to high-risk lymphoma and sarcoma, while molecular subtype definition extends to esophageal adenocarcinoma. Hi-C and fluorescence in situ hybridization support diagnosis of oncogene rearrangements, and ecDNA profiling exposes amplification in osteosarcoma. Clinical outcome and relapse analyses define risk, while a MYC/GSPT1 degrader provides a preclinical treatment strategy for hematologic malignancies. The shared direction is molecular stratification of aggressive tumors rather than one unified treatment strategy.

    6 papers · 42.9%

  • MYC, Ferroptosis and Metabolism

    MYC stabilization connects glycolytic rewiring in diabetic retinopathy with ferroptosis control in colorectal cancer. DNMT1-mediated methylation of FBXO32 is linked to MYC stability, while FTH1 and GPX4 suppression of ferroptosis accompanies oxaliplatin resistance. The work points toward combining redox or protein-stability interventions with standard treatment rather than treating MYC as an isolated driver. Whether these mechanisms are therapeutically tractable across tissues remains open.

    2 papers · 14.3%

  • Others — MYC-Linked Disease Mechanisms

    Mitochondrial regulation is emerging as a recurring route to MYC-linked disease biology, with breast cancer providing the main therapeutic context. Berberine-associated mitophagy changes, TIMM17A/TIMM17B synthetic lethality and a stapled MYC degrader point toward attacking MYC-dependent mitochondrial states. Network toxicology instead nominates EGFR, CXCL8 and AKT1 among microplastic-associated breast cancer targets. The mixed disease settings leave efficacy and mechanism unresolved.

    6 papers · 42.9%

PARADIGM SHIFT

MYC is directly degradable and therapeutically targetable rather than intrinsically “undruggable”

The hematologic malignancy study of the dual MYC/GSPT1 degrader GT19630 and the triple-negative breast cancer study of the stapled-peptide degrader MAX-7 independently show direct MYC-directed therapies producing substantial antitumor effects in distinct disease models 42607078Aug 42444318Jul. The assumed failure of direct MYC targeting, and its characterization as “undruggable,” is challenged by GT19630’s direct binding and low-nanomolar activity in leukemia, lymphoma, and myeloma models, together with in vivo efficacy, and by MAX-7’s cell-permeable, lysosome-dependent depletion of MYC and tumor regression in a 4T1 xenograft. The resulting change is therapeutic rather than merely descriptive: direct degradation of MYC is presented as a viable strategy across hematologic and solid-tumor models.

Papers

The 14 papers from the last 6 months that study myc directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Oncogene Alterations in Aggressive Tumors (6)
  1. A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
  2. Paraneoplastic Myopathy as a Possible Initial Presentation of Sporadic Burkitt Lymphoma in an Immunocompetent Adult: A Case Report. Cancer reports (Hoboken, N.J.) · 1 Sept 2026 PMID 42680716
  3. A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies. Blood · 17 Aug 2026 PMID 42607078
  4. SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
  5. Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood advances · 10 Jul 2026 PMID 42431614
  6. Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood advances · 17 Jun 2026 PMID 42308239
MYC, Ferroptosis and Metabolism (2)
  1. Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4. Cancer chemotherapy and pharmacology · 6 Aug 2026 PMID 42560559
  2. DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. Journal of bioenergetics and biomembranes · 25 Jun 2026 PMID 42348038
Others — MYC-Linked Disease Mechanisms (6)
  1. MYC primes a paralog synthetic lethality involving the mitochondrial translocase subunits TIMM17A and TIMM17B and N-Acetylaspartate. Science advances · 6 Nov 2026 PMID 42993843
  2. Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. Molecular diversity · 28 Aug 2026 PMID 42665765
  3. Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study. Cell biochemistry and biophysics · 26 Aug 2026 PMID 42645668
  4. Integrating network toxicology and transcriptomics to identify CXCL8, EGFR, PTPRC, MYC, and AKT1 as key targets of microplastic-induced miscarriage. Medicine · 22 Aug 2026 PMID 42629697
  5. Discovery of Stapled Peptide MYC Degrader with Potent In Vivo Activities for Triple-Negative Breast Cancer Therapy. Journal of medicinal chemistry · 14 Jul 2026 PMID 42444318
  6. A pH‑responsive hydrogel delivering ISOC1 modRNA attenuates disc degeneration by promoting BIRC6‑mediated MYC degradation and inhibiting SBSN expression. Journal of nanobiotechnology · 28 Jun 2026 PMID 42366417

By study type

Observational studies and case reports (1)
  1. Paraneoplastic Myopathy as a Possible Initial Presentation of Sporadic Burkitt Lymphoma in an Immunocompetent Adult: A Case Report. Cancer reports (Hoboken, N.J.) · 1 Sept 2026 PMID 42680716
Human data, design not indexed (5)
  1. Integrating network toxicology and transcriptomics to identify CXCL8, EGFR, PTPRC, MYC, and AKT1 as key targets of microplastic-induced miscarriage. Medicine · 22 Aug 2026 PMID 42629697
  2. SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
  3. Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood advances · 10 Jul 2026 PMID 42431614
  4. DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. Journal of bioenergetics and biomembranes · 25 Jun 2026 PMID 42348038
  5. Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood advances · 17 Jun 2026 PMID 42308239
Preclinical: animal, cell and lab studies (4)
  1. MYC primes a paralog synthetic lethality involving the mitochondrial translocase subunits TIMM17A and TIMM17B and N-Acetylaspartate. Science advances · 6 Nov 2026 PMID 42993843
  2. A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies. Blood · 17 Aug 2026 PMID 42607078
  3. Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4. Cancer chemotherapy and pharmacology · 6 Aug 2026 PMID 42560559
  4. Discovery of Stapled Peptide MYC Degrader with Potent In Vivo Activities for Triple-Negative Breast Cancer Therapy. Journal of medicinal chemistry · 14 Jul 2026 PMID 42444318
Unclassified: not yet indexed with MeSH (4)
  1. A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
  2. Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. Molecular diversity · 28 Aug 2026 PMID 42665765
  3. Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study. Cell biochemistry and biophysics · 26 Aug 2026 PMID 42645668
  4. A pH‑responsive hydrogel delivering ISOC1 modRNA attenuates disc degeneration by promoting BIRC6‑mediated MYC degradation and inhibiting SBSN expression. Journal of nanobiotechnology · 28 Jun 2026 PMID 42366417